The company’s 2025 investment budget amounts to nearly EUR10 million.
“For late 2025 and 2026, the investment budget will continue to focus on two main directions: supporting strategic brands in the portfolio and the development of new products and innovative formulas via our own R&D center,” said Catalin Vicol, Biofarm general manager.
Biofarm has two drug plants in Bucharest.
For 2025, the company targets RON325 million turnover, up 14% year-on-year.
(English version by Catalina Apostoiu)